Cardiex sales and operations update

Cardiex (ASX: $CDX) has released a sales and operations update, highlighting its strong performance in FY24. The company is on track to exceed $12m in revenues for FY24, compared to $6.01m for FY23. Sales to the research market have been the highest in the previous 6 months, with a confident outlook for achieving a record year of research sales by financial year-end. Additionally, Cardiex is actively engaging in dialogue on multiple new pharma opportunities to extend its sales growth into FY25.

Executive Commentary on Recent Progress

We're pleased to report the significant progress we've made across our business units. The strong performance in FY24, with record revenues and high sales to the research market, reflects the effectiveness of our strategies and the quality of our products. We are also excited about the upcoming launch of the Conneqt Pulse and the partnerships we have secured, which will further enhance our market presence and customer reach. The success of the Cardiex Arterial Research Initiative and the progress on new FDA clearance submissions demonstrate our commitment to driving the field of arterial health forward and expanding our global footprint. We appreciate the ongoing support from our shareholders and look forward to updating them following the current financial year-end.

Summary of Cardiex Sales and Operations Update

Cardiex has reported strong sales performance in FY24, with a projected revenue exceeding $12m, indicating a significant growth compared to the previous financial year. The company's focus on new pharma opportunities and the upcoming launch of the Conneqt Pulse reflect its commitment to sustained growth and innovation. The partnerships with PhysioAge and Heartbeat Health are expected to expand Cardiex's market presence and provide additional value to its customers. The success of the Cardiex Arterial Research Initiative highlights the company's dedication to advancing arterial health research and supporting innovative projects globally. Furthermore, the progress on new FDA clearance submissions underscores Cardiex's efforts to expand its product offerings and market reach. With a strong outlook for FY25, Cardiex remains committed to enabling better, more productive, and longer lives through its suite of medical and home health devices and digital solutions.